文献速递肝病

2008至2018年中国非酒精性脂肪性肝病负担意外快速增加:系统综述与荟萃分析

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis.
PubMed 文献 · Hepatology · 2019-01-01

该系统综述与荟萃分析检索2008至2018年5个英文数据库和3个中文数据库,纳入392项研究、共2,054,554人,中国NAFLD全国患病率为29.2%,在中老年、男性、西北地区和台湾、人均GDP超过10万元地区及维吾尔族和回族人群中疾病负担更重。NAFLD与肝外肿瘤、糖尿病、心血管疾病和代谢综合征发病率正相关,中国人可能在临床试验中代表不足。结论为中国NAFLD负担在短期内意外快速增加,需提高认识和采取紧急行动。

要点

  • 中国NAFLD全国患病率为29.2%,中老年、男性、西北和台湾地区负担更重。
  • NAFLD与肝外肿瘤、糖尿病、心血管疾病和代谢综合征发病率正相关。
  • 中国人在NAFLD临床试验中的代表比例低于其占NAFLD人群的比例。

核心结论

  • 中国在短期内经历了NAFLD负担的意外快速增加,需提高认识并采取紧急行动以控制NAFLD流行。

研究设计与样本

  • 系统综述与荟萃分析,检索2008至2018年5个英文文献数据库和3个中文数据库,纳入392项研究、共2,054,554人。

主要发现

  • 中国NAFLD全国患病率为29.2%,疾病负担在中老年、男性、西北地区和台湾、人均GDP超过10万元地区及维吾尔族和回族人群中更重。
  • 中国关于NAFLD自然史和并发症的原创研究稀缺,多项研究显示NAFLD与肝外肿瘤、糖尿病、心血管疾病和代谢综合征的发病率正相关。
  • 中国人群可能因脂质代谢调节基因中非同义突变更频繁而具有更高的NAFLD遗传风险。
  • 超声是中国检测NAFLD的主要影像工具,血清检测和风险分层算法用于NAFLD分期仍在研究中,NAFLD特异性药物治疗仍在临床试验中。
  • 中国人在此类NAFLD临床试验中的代表比例低于其占NAFLD人群的比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta-analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies with a population of 2,054,554 were included. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle-aged, males, those in northwest China and Taiwan, regions with a gross domestic product per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed that NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease and metabolic syndrome. The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared with their proportion of the NAFLD population in such trials. Conclusion: China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhou F, Zhou J, Wang W, et al. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019. PMID: 31070259. doi:10.1002/hep.30702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。